Femstat 3, Gynazole 1
Classifications: azole antifungal antibiotic; Therapeutic: antifungal; antibiotic
Pregnancy Category: C
Imidazole derivative with antifungal activity. Alters fungal cell membrane permeability, permitting loss of phosphorous
compounds, potassium, and other essential intracellular constituents with consequent loss of ability to replicate. Action
takes place primarily on medicated infected surface tissues.
Has fungicidal effect as well as effectiveness against some gram-positive bacteria.
Local treatment of vulvovaginal candidiasis.
Pregnancy (category C). Safety in children <12 y is not established.
Hypersensitivity to azole antifungals; HIV patients; diabetes mellitus; lactation.
Route & Dosage
Adult: Topical 1 applicator full intravaginally h.s. for 3 d, may be extended another 3 d if needed
Pregnant women: Topical 1 applicator full intravaginally h.s. for 6 d
- Continue treatment even during menstruation.
- Store medication at 15°30° C (59°86° F); avoid extreme temperature and freezing.
Adverse Effects (≥1%)Urogenital:
Vulvar or vaginal burning, vulvar itching, discharge, soreness, swelling; urinary frequency and burning. Skin:
Itching of fingers. CNS:
Small amount absorbed systemically from intravaginal administration. Distribution:
Crosses placenta in animals. Metabolism:
In liver. Elimination:
In both urine and feces within 47 d. Half-Life:
Assessment & Drug Effects
- Monitor for therapeutic effectiveness. Candidiasis in nonpregnant women is usually controlled in 3 d.
Patient & Family Education
- Take medication exactly as prescribed; do not increase or decrease dosage or discontinue or extend treatment period. Contact
physician if symptoms (vaginal burning, discharge, or itching) persist; drug may be discontinued if acute irritation occurs.
- Patient's sexual partner should wear a condom during intercourse.